Zurich, Switzerland

Robert Maka

This inventor holds 1 USPTO granted patent. Top assignee: Unversität Zürich. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Maka. Retrieved from https://idiyas.com/inventor/robert-maka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Robert Maka

Introduction

Robert Maka is an accomplished inventor based in Zurich, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work is recognized for its potential impact on medical treatments and research.

Latest Patents

Robert Maka holds a patent for a CD25-biased anti-IL-2 antibody. This innovative antibody has implications for therapeutic applications, particularly in the treatment of various diseases.

Career Highlights

Robert Maka is affiliated with Universität Zürich, where he conducts research and collaborates with other experts in the field. His work at the university has allowed him to explore new frontiers in biotechnology and contribute to scientific advancements.

Collaborations

He has worked alongside notable colleagues such as Onur Boyman and Ufuk Karakus. Their collaborative efforts have further enhanced the research output and innovation at Universität Zürich.

Conclusion

Robert Maka's contributions to biotechnology through his patent and collaborative research highlight his role as a significant inventor in the field. His work continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…